daromun: Clinical Trials

7 trials of daromun, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 recruiting, 2 unknown, 1 completed. 7 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 27Recruiting 4, Unknown 2, Completed 1

Follow daromun: new trials by email Literature Review of daromun trials Research Report on daromun

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma
L19IL2/L19TNF - Locally Advanced Cutaneous Squamous Cell Carcinoma
Phase 2RecruitingPhilogen S.p.A.922026-10-292026-11-13
L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)
L19IL2, L19TNF, L19IL2/L19TNF - Locally Advanced Basal Cell Carcinoma
Phase 2RecruitingPhilogen S.p.A.1802026-09-282026-11-10
L19IL2/TNF in Patients With Basal Cell Carcinoma
L19IL2/L19TNF - Locally Advanced Basal Cell Carcinoma
Phase 2RecruitingPhilogen S.p.A.922026-09-012026-07-21
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients
L19IL2, L19TNF, L19IL2/L19TNF - Melanoma Stage III, Melanoma Stage IV
Phase 2RecruitingPhilogen S.p.A.1622024-07-122026-09-02
L19IL2/L19TNF in Skin Cancer Patients
L19IL2/L19TNF - BCC - Basal Cell Carcinoma, SCC - Squamous Cell Carcinoma
Phase 2UnknownPhilogen S.p.A.702023-03-092023-10-06
Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients
L19IL2 +L19TNF - Carcinoma, Basal Cell, Carcinoma, Cutaneous Squamous Cell
Phase 2UnknownPhilogen S.p.A.402020-09-022023-10-10
Intratumoral Administration of L19IL2/L19TNF
L19IL2+L19TNF - Malignant Melanoma, Skin
Phase 2CompletedPhilogen S.p.A.212012-12-012015-05-27

Conditions studied

Carcinoma, Basal Cell (4)  ·  Melanoma (2)  ·  Carcinoma (1)  ·  Carcinoma, Merkel Cell (1)  ·  Carcinoma, Squamous Cell (1)  ·  Sarcoma, Kaposi (1)

Sponsors

Philogen S.p.A. (7)

Countries

Italy (6)  ·  Germany (5)  ·  Spain (4)  ·  United States (4)  ·  Greece (3)  ·  France (1)  ·  Poland (1)  ·  Switzerland (1)

Top investigators

Danielle Bello (1)  ·  Mario Santinami, Dr (1)

NIH funding

2025 (3)